ArticlebioRxiv : the preprint server for biology2026
The NanoBridge system for targeted post-translational modification of challenging proteins.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The ability to edit posttranslational modifications (PTMs) of endogenous proteins within cells is essential for precisely delineating the biological roles of PTMs and for developing targeted therapeutics. While the paradigm of chemically induced proximity (CIP) has advanced this field by enabling the recruitment of PTM enzymes to the proximity of proteins of interest (POIs), CIP requires small-molecule binders that are difficult to obtain for proteins without well-defined binding pockets. In principle, the use of biomolecular ligands that target disordered proteins should overcome this limitation. In this work, we developed the NanoBridge as a modular and generalizable platform to enable PTM editing of challenging POIs in live cells. The NanoBridge employs biologic binders to transiently direct the small protein tag FKBP12
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.